Answers are grounded in this paper and cite their sources.
The long blood circulation time of albumin has been clinically utilized as a half-life extension technology for improved drug performance. The availability of one free thiol for site-selective chemical conjugation offers an alternative approach to current genetic fusion and association-based products. This special report highlights important factors for successful conjugation that allows the reader to design and evaluate next-generation albumin conjugates. Albumin type, available conjugation chemistries, linker length, animal models and influence of conjugation on albumin pharmacokinetics and drug activity are discussed.
No takes yet. Share an insight, caveat, or question.
Caspersen et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: